glp-1 drugs in development Trends the of Receptor Agonists GLP-1 Genetics: How Genes Affect

Recent advances of GIP and future horizons

FDA approves weight management drug for patients aged 12

(In fact, exendin-4 has to be cleared out through the kidneys, which takes time.) Successful clinical trials in humans were conducted in the early 2000s

Weight Regain After Discontinuation Is the Rule, Not the Exception Without addressing: Insulin sensitivity Muscle preservation Nutrient status Lifestyle structure Most patients experience partial or full weight regain after stopping GLP-1 therapy

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

doi: 10.1016/j.peptides.2018.09.002 139 HuangJZhaoJGengXChuWLiSChenZJet al